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ABSTRACT
Chronic respiratory diseases are a major cause of mor-
bidity and mortality. Asthma and chronic obstructive
pulmonary disease (COPD) combined affect over
500 million people worldwide. While environmental fac-
tors are important in disease progression, asthma and
COPD have long been known to be heritable with
genetic components playing an important role in the
risk of developing disease. Identiﬁcation of genetic vari-
ation contributing to disease progression is important
for a number of reasons including identiﬁcation of risk
alleles, understanding underlying disease mechanisms
and development of novel therapies. Genome-wide
association studies (GWAS) have been successful in
identifying many loci associated with lung function,
COPD and asthma. In recent years, meta-analyses and
improved imputation have facilitated the growth of
GWAS in terms of numbers of subjects and the number
of single nucleotide polymorphisms (SNP) that can be
interrogated. As a consequence, there has been a signif-
icant increase in the number of signals associated with
asthma, COPD and lung function. SNP that have shown
association with lung function reassuringly show a sig-
niﬁcant overlap with SNP associated with COPD giving
a glimpse at pathways that may be involved in COPD
mechanisms including genes in, for example, develop-
mental pathways. In asthma, association signals are
often in or near genes involved in both adaptive and
innate immune response pathways, epithelial cell
homeostasis and airway structural changes. The chal-
lenges now are translating these genetic signals into a
new understanding of lung biology, understanding how
variants impact health and disease and how they may
provide opportunities for therapeutic intervention.
Key words: asthma, chronic obstructive pulmonary disease,
genome-wide association, lung function.
INTRODUCTION
Chronic obstructive respiratory diseases are common
and are leading causes of morbidity and mortality. The
most common are chronic obstructive pulmonary dis-
ease (COPD) and asthma. Worldwide in 2015, COPD
and asthma resulted in the death of approximately 3.2
million and 400 000 people, respectively, while affect-
ing over 500 million people combined.1 Asthma is char-
acterized by chronic inﬂammation, reversible airway
obstruction and airway hyper-responsiveness, whereas
COPD is deﬁned by irreversible obstruction of the air-
ways with emphysema and/or chronic bronchitis.2,3
Currently, there is no cure for asthma or COPD and
treatment focuses on the management of symptoms
which can successfully improve the quality of life of
patients. Recently, greater understanding of disease
mechanisms and the speciﬁc subtypes of disease have
led to the introduction of more tailored treatments
such as anti-IgE (immunoglobulin E) and/or anti IL-5
therapy in asthma.4 However, further insight is needed
into disease mechanisms in order to develop more
effective therapies.
COPD and asthma are heterogeneous diseases with
both environmental and genetic factors contributing to
disease development and progression. Smoking
tobacco is well known as the major risk factor for
developing COPD; however, only 10–20% of heavy
smokers develop COPD.
Identiﬁcation of genetic variants and disease genes is
important for a number of reasons including (i) to
identify risk alleles which might in time help with early
diagnosis and possible disease prevention; (ii) the
development of novel therapeutic interventions; and
(iii) the identiﬁcation of subgroups of patients who are
most likely to gain beneﬁt from particular therapies, an
approach usually referred to as personalized or preci-
sion medicine. In addition, these studies can help to
unravel the complex gene–environment interactions
that lead to disease.
In the current review, we outline the signiﬁcant pro-
gress that has been made in identifying genetic variants
of relevance to asthma and COPD with a particular
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focus to those identiﬁed in genome-wide association
studies (GWAS).
Heritability of lung function, COPD and
asthma
It is well established that asthma and COPD run in
families. A twin study in 34 782 Danish twins suggested
that genetic factors accounted for 34% of the variation
of asthma age of onset with the risk of asthma for a co-
twin of an affected twin being higher in monozygotic
than in dizygotic twins.5
Lung function measurements are used in the diagno-
sis of obstructive pulmonary diseases making them use-
ful quantitative traits for studying the genetics of COPD
with the additional statistical power beyond case/control
approaches. The most commonly used measures of lung
function are forced expiratory volume in 1 s (FEV1,), the
volume of air that can forcibly be blown out in 1 s;
forced vital capacity (FVC), the volume of air that can
forcibly be blown out after full inspiration; and the
FEV1/FVC ratio. Population-based studies on families
with respiratory disease have provided evidence for
familial aggregation of spirometric measurements and
the heritability of lung function measures have been
estimated to range anywhere from 10% to 80%.6–10
The ﬁrst gene identiﬁed to be associated with COPD,
speciﬁcally emphysema, was SERPINA1 which encodes
alpha-1 antitrypsin (A1AT). A1AT deﬁciency, caused by
mutations in A1AT, affects up to 1 in 5000 individuals in
Europe.11 This deﬁciency was ﬁrst identiﬁed in 1963 by
Laurell and Eriksson who described individuals who have
approximately 10% of normal A1AT levels in their serum.
While some individuals with A1AT deﬁciency have
emphysema, only about 1–3% of COPD sufferers have the
deﬁciency.12 Therefore, despite the well-understood
genetic and molecular causes of COPD in this small sub-
set of patients, it is still largely unknown what the under-
lying disease mechanisms in the majority of sufferers are.
METHODS FOR STUDYING GENETICS
OF RESPIRATORY DISEASE
Until recently, identifying genes and variants involved
in respiratory disease has been challenging. This is in
part due to the heterogeneity in patient phenotypes. It
is also due to the likelihood that complex, common
diseases are driven by a combination of common
genetic variants each contributing small phenotypic
effects combined with a signiﬁcant environmental com-
ponent. This means that variation in phenotype is likely
due to a combination of different genotypes making
unravelling genetic causes of disease difﬁcult.
Early genetics: Linkage and candidate gene
studies
Linkage analysis is a method of genetic mapping which
allows the identiﬁcation of genetic variants that cose-
gregate with disease through generations based on
their chromosomal location. Linkage analysis has been
effective in identifying genetic variants causing mono-
genic disorders (e.g. cystic ﬁbrosis). However, this
method has proved less useful for asthma and COPD
due to the lack of sufﬁcient power and the complex
genetic basis of these diseases.
Despite these limitations, there were a number of
studies which found regions of linkage with lung func-
tion and COPD phenotypes on chromosomes 2, 4, 6, 8,
12 and 19.13–17 Similarly, in asthma, several loci were
identiﬁed including but not limited to IL13, TNF,
ADAM33, IL4RA, DPP10, PHF11, NPSR1, HLA-G,
CYFIP2, IRAK3, COL6A5, OPN3/CHML and TBXA2R.18,19
Candidate gene studies are a hypothesis-driven
approach in which genes postulated to impact disease,
due to known role in disease biology and/or chromo-
somal location, are investigated. In asthma and COPD,
over 100 genes have been identiﬁed as potentially rele-
vant; however, these studies have been limited by
power and lack of replication of ﬁndings. For more
details of early genetic studies, see excellent reviews for
lung function and COPD20 and asthma.18
Genome-wide association studies
In 2006, Dewan et al. performed a GWAS identifying a
variant in the promoter region of HTRA1 to be signiﬁ-
cantly associated with macular degeneration.21 Since
this ﬁrst proof-of-concept study, GWAS have become
highly effective for the discovery of disease genes
across a large number of complex traits and diseases
due to the rapid advances in genotyping technology
and projects such as the Human Genome Project and
the HapMap project.22–25
The basic concept of GWAS is that hundreds of thou-
sands of common single nucleotide polymorphisms
(SNP) (generally >5% allele frequency) are tested for
association with a speciﬁc trait; for example, a lung
function phenotype such as FEV1 or a disease category
such as asthma. A typical GWAS utilizes a case–control
design whereby the allele frequency of SNP in the cases
(individuals with the trait or disease) is compared to
the allele frequency of SNP in the controls (Fig. 1).
Individuals are genotyped on an SNP array, which is
a chip-based microarray technique that is used to assay
hundreds of thousands to millions of SNP. Currently,
there are two platforms commonly used for GWAS,
which differ slightly in their methods to detect SNP var-
iation in genomic DNA. First, Affymetrix (Central
Expressway, Santa Clara, CA, USA) uses an approach
by which short DNA sequences are printed on a spot
on the chip which recognizes a speciﬁc allele by
hybridization. Alternatively, the Illumina (Illumina
Way, San Diego, CA, USA) platform uses a bead-based
approach with slightly longer DNA sequences to detect
speciﬁc alleles.26
A standard GWAS involves examining association of
>500 000 SNP spanning the entire genome as well as
the platform, the individual SNP to be assayed is an
important consideration as it is not currently feasible to
assay all known SNP in the human genome. To capture
the maximum amount of information possible, panels
are used that contain SNP that tag haplotype blocks. A
haplotype block is a group of SNP that are statistically
likely to be inherited together. Therefore, by choosing
to include SNP on the panel that tag haplotype blocks,
it is possible to infer the genotype for many more SNP
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than those that are actually on the panel. Other consid-
erations for SNP selection generally are speciﬁc to the
type of study. For example, the UK BiLEVE custom
array was designed to (i) measure rare coding variants
(variants which alter amino acid sequences);
(ii) provide a framework which would allow optimum
imputation of non-genotyped common or low fre-
quency variants (therefore increasing coverage) and
(iii) optimize coverage of genes and loci which have
already been linked to respiratory health and/or dis-
ease (allows ﬁne mapping of regions of interest).27
The allele frequency of each SNP is tested for associa-
tion with the trait in question, requiring a stringent level
of statistical signiﬁcance due to the large number of
tests. Typically P < 5 × 10−8 is considered signiﬁcant to
show genome-wide association. This stringent thresh-
old is important to avoid the detection of false positives,
which is more likely when there are a large number of
variants (and therefore hypotheses) being tested. A
genome-wide scan of common variants is equivalent to
approximately 1 million independent tests, hence this
value represents Bonferroni correction.28,29 This level of
stringency therefore requires large sample sizes for a
signal to reach genome-wide signiﬁcance.
Although, because of the improved ability to impute
genotypes which are not directly genotyped, most
recent studies where minor allele frequencies of less
than 5% are being assessed, the required signiﬁcance
level would be set at P < 5 × 10−9.
Replication of ﬁndings in an independent cohort is
also standard practice to validate ﬁndings. Once SNP
are validated for association, further in silico, in vitro
and in vivo studies are required to explore the biologi-
cal mechanisms underlying the association.
The advantage of GWAS is that they are mostly
hypothesis free in the sense that associations are
searched for over the entire genome. However, they
are limited in that association signals are not directly
informative with respect to the biology underlying the
association signal and therefore further analysis and
functional genetics are required to elucidate the
causal variant(s) and mechanisms underlying the
signal.30
Early GWAS
For asthma, the ﬁrst GWAS was published in 2007
using 994 asthmatic patients and 1243 controls which
identiﬁed that variants which regulate the expression of
ORMDL3 are associated with an increased risk of child-
hood asthma.31 Similarly, early GWAS of lung function
showed some success in identifying a number of loci
associated with lung function and COPD. These loci
include HHIP at the 4q31 locus, CHRNA3/5 at 15q25
and FAM13A at 4q22.32–34
Meta-analyses and imputation
Early GWAS showed great success in identifying novel
loci associated with lung function, COPD and asthma;
however, these studies also identiﬁed that greater sta-
tistical power would be required to identify genetic var-
iation associated with modest effect sizes. As a result of
these studies, meta-analyses were used to analyse the
results of independent GWAS together thereby increas-
ing the statistical power for novel loci discovery.
Imputation describes a method whereby genetic var-
iants which were not directly genotyped can be pre-
dicted with a degree of conﬁdence.35 This is done using
reference genomes which are now widely available,
thanks to studies such as the 1000 genomes, 10 000
genomes and the HapMap projects.36 Imputation gives
increased power because the reference panel is more
likely to contain the causal variant than the original
array while also facilitating ﬁne-mapping of the region
by giving a high-resolution overview of an association
signal over a locus. In addition, imputation allows
GWAS typed with different arrays to be combined to
the reference panel, which is essential to combine
independent GWAS for meta-analyses.
GWAS in lung function and COPD
In 2010, the SpiroMeta and Charge consortium pub-
lished back-to-back papers describing meta-analyses of
GWAS on FEV1 and FEV1/FVC.
37,38 These two studies
had signiﬁcantly greater numbers of subjects than pre-
viously used with the SpiroMeta study using 20 288
individuals for discovery analysis. This was followed up
by a meta-analysis of 32 184 genotyped individuals
with in silico association data from the Charge consor-
tium’s 21 092 individuals and an additional 883 individ-
uals from the Health 2000 study.38 The SpiroMeta study
replicated the association locus at 4q31 (HHIP) and
identiﬁed ﬁve additional novel loci associated with
either FEV1 or FEV1/FVC in or near GSTCD, HTR4,
Figure 1 Genome-wide association studies test the frequency
of common SNP between cases and controls. SNP, single nucle-
otide polymorphism.
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AGER (Advanced Glycation End Product Receptor) and
THSD4.38 The Charge meta-analyses included 20 890
participants of European ancestry in the discovery
phase and 20 228 individuals from the SpiroMeta con-
sortium in the replication cohort.37 This study identi-
ﬁed another nine loci associated with lung function.
HHIP, GPR126, ADAM19, AGER-PPT2, FAM13A,
PTCH1, PID1 and HTR4 were associated with FEV1/
FVC while one locus was associated with FEV1 which
was INTS12-GSTCD-NPNT, replicating results from the
SpiroMeta study.37,38
Since these ﬁrst meta-analyses of GWAS of lung func-
tion, the scale of the studies has increased signiﬁcantly
with respect to both the number of subjects and the
number of markers and this has facilitated the growth in
the number of signals found. For example, following up
these studies in 2011, meta-analyses of 23 lung function
GWAS from the SpiroMeta and CHARGE consortiums
were published which used a total of 48 201 individuals.
The result was the identiﬁcation of 16 additional novel
loci for lung function including 12 novel loci for FEV1/
FVC, 3 novel loci for FEV1 and 1 locus for both traits.
39
In addition to the novel loci, the study provided further
evidence for 10 previously identiﬁed loci.39
In more recent years, meta-analysis using SpiroMeta
and CHARGE GWAS was performed by Loth et al. in
2014, this time focused to FVC. This analysis used
52 253 individuals from 26 studies, following up the top
associations in 32 917 individuals. They identiﬁed six
novel loci associated with FVC at EFEMP1, BMP6,
MIR129-2-HSD17B12, PRDM11, WWOX and KCNJ2 as
well as association with known signals at GSTCD and
PTCH1.40 While most studies have focused on cross-
sectional lung function, a study of longitudinal change
in adult lung function provided suggestive evidence for
association at novel loci IL16/STARD5/TMC3 on chro-
mosome 15 and ME3 on chromosome 11.41
A further 16 novel signals were identiﬁed in a 2015
SpiroMeta paper in or near ENSA, RNU5F1, KCNS3,
AK097794, ASTN2, LHX3, CCDC91, TBX3, TRIP11,
RIN3, TEKT5, LTBP4, MN1 and AP1S2 including novel
signals in known loci GPR126 and NPNT.42 A study
around the same time in the UK Biobank cohort identi-
ﬁed six novel genome-wide signiﬁcant signals of associ-
ation with extremes of FEV1. This study selected
individuals from the middle and extremes of the FEV1
distribution among heavy smokers and never-smokers.
Signals of association were found at four novel loci
KANSL1, TSEN54, TET2 and RBM19/TBX5 and two
novel signals from previously reported loci NPNT and
HLA-DQB1/HLA-DQA2.43
The most recent published large-scale lung function
GWAS almost doubled the number of signals that have
been associated with lung function by identifying
43 new signals, increasing the number of independent
signals to 97 (Fig. 2).43 There was enhancement in
genes for epigenetic regulation pathways, elastic ﬁbres
and development.43
As one would expect, many of these signals have also
shown an association with COPD (Fig. 3).27,32,34,37–40,42–47
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Figure 2 Genome-wide association results for FEV1 (top), FEV1/FVC (middle) and FVC (bottom). Previously reported signals are
highlighted in dark blue (except signals with P > 5 × 10−4 in this study); and novel signals are coloured in red. Signals are highlighted
for the trait with which they showed strongest association only. The red and blue lines correspond to the genome-wide signiﬁcance
level (P = 5 × 10−8, −log10P = 7.3) and the threshold used to select signals for follow-up in stage 2 (P = 5 × 10−7, −log10P = 6.3), respec-
tively. Labels show the nearest gene to the novel sentinel variants. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
(Reproduced from Wain et al.,43 with permission). Black and grey lines are used to show individual chromosomes.
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A number of studies have succeeded in ﬁnding
disease-speciﬁc SNP associated with COPD phenotypes
including emphysema, COPD exacerbations, chronic
bronchitis, airway responsiveness and severity of dis-
ease, for example AGER SNP rs2070600 and emphy-
sema and gas trapping.48 Signiﬁcant association has
been found for a number of loci already associated
with lung function with COPD diagnosis including
FAM13A, TNS1, INTS12/GSTCD/NPNT, HTR4, HHIP,
AGER, TSHD4, CHRNA5/CHRNA3 and
ADAM19.34,43,45–47,49–53
A 2017 GWAS using 15 256 COPD cases and 47 936
controls identiﬁed 22 loci at genome-wide signiﬁcance
which included 13 new COPD associations, 9 of which
have previously been associated with lung function.44
The remaining four loci (EEFSEC, DSP, MTCL1 and
SFTPD) were novel.44 Also in 2017, Wain et al. analysed
95 of 97 known independent signals associated with
lung function for replication with association with
COPD. Of the 95, 51 showed nominal association
(P < 0.05) and 30 showed association with COPD sus-
ceptibility.43 This ﬁnding that there is an overlap
between genetic variants associated with lung function
and COPD provides conﬁdence that (i) the locus is a
true association and (ii) it is important for COPD. By
knowing that a variant contributes to lung function and
a speciﬁc COPD phenotype, we can begin to discover
the biological mechanisms that underlie the association
with disease.
GWAS in asthma
Asthma is a heterogeneous condition involving a num-
ber of sub-phenotypes, which may have different clini-
cal presentations, disease mechanisms, underlying
causes and genetic associations. As of May 2018, there
have been 28 GWAS on asthma according to the
National Human Genome Research Institute (NHGRI)-
European Bioinformatics Institute (EBI) GWAS cata-
logue (Table 1).69 Multiple studies have begun to try to
unravel the complex underlying causes of these sub-
phenotypes. For example, the ORMDL3/GSDMB/ZPB2
locus on chromosome 17 is associated with childhood
asthma, severe asthma and asthma with allergic rhini-
tis.31,56,63,68 IL33 is involved in the recruitment and acti-
vation of inﬂammatory cells, and SNP in this gene
region are associated with childhood severe asthma
with exacerbation and asthma with an allergic rhinitis
diagnosis.56,58,62,63 Interestingly, SNP spanning IL1RL1,
the IL-33 receptor, are associated with childhood
asthma, severe asthma and with a diagnosis of allergic
rhinitis.56,63,68 For an excellent review of GWAS in
asthma up until 2016, see the study by Vicente et al.70
A 2017 study found a further four novel loci after a
meta-analysis on 21 644 European American and Afri-
can American individuals.67 6p21.31, 9p21.2 and
10q21.3 were the loci identiﬁed in the European Ameri-
can population with TEK at the 9p21.2 locus of speciﬁc
interest due to its known involvement in remodelling
in the lung.71,72 In the African American population,
PTGES on 9q34.11 was identiﬁed as a novel locus.67
To date, the largest GWAS of asthma was completed
in 2016 and included 28 399 cases of self-reported
asthma and 128 843 non-asthmatic controls and identi-
ﬁed 27 loci contributing to the risk to develop asthma.54
This study identiﬁed many of the previous associations
and identiﬁed new associations at ADAMTS4,
D2HGDH, CLEC16A, LRP1, ADORA1, BACH2, PEX14
and STAT6.54 Several of these loci have recently been
replicated using 23 948 self-reported asthma cases and
Figure 3 Reported genes associated with lung function and COPD. The diagram shows the genes which have association signals for
lung function and COPD and the genes which have signals for both. The signals displayed are those which showed the highest levels
of association, while additional signals which showed less signiﬁcant association are not shown. In addition to this overlap, the genetic
risk score based on 95 lung function variants is highly predictive of COPD risk.43 COPD, chronic obstructive pulmonary disease.
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Table 1 Genetic loci associated with asthma and asthma phenotypes in GWAS
Chromosome Phenotype (s) Gene(s) reported Reference
1 Asthma PEX14 Pickrell (2016)54
1 Asthma IL6R Ferreira (2011)55
1 Asthma PYHIN1 Torgerson (2011)56
1 Asthma ADAMTS4 Pickrell (2016)54
1 Asthma CD247 Pickrell (2016)54
1 Asthma TNFSF18 Pickrell (2016)54
1 Moderate–severe childhood
asthma
DENND1B Sleiman (2010)57
1 Asthma ADORA1 Pickrell (2016)54
2 Asthma ID2 Pickrell (2016)54
2 Asthma, childhood asthma +
exacerbations, asthma + hay
fever
IL1R1/IL18R1 Bonnelykke (2014),58 Pickrell
(2016),54 Ramasamy (2012),59
Torgerson (2011),56 Demenais
(2018),60 Gudbjartsson (2009),61
Ferreira (2014),62 Moffatt (2010)63
2 Asthma D2HGDH Pickrell (2016)54
3 Asthma LPP Pickrell (2016)54
4 Asthma, asthma + hay fever TLR1 Pickrell (2016),54 Ferreira (2014)62
4 Asthma USP38 Hirota (2011)64
5 Mild–moderate childhood
asthma with BHR
PDE4D Himes (2009)65
5 Asthma, asthma + hay fever TSLP/SLC225A46/WDR36 Torgerson (2011),56 Hirota (2011),64
Ferreira (2014),62 Pickrell
(2016),54 Demenais (2018),60
Gudbjartsson (2009),61
5 Asthma, childhood asthma +
exacerbations
IL13/RAD50/IL4 Pickrell (2016),54 Bonnelykke
(2014),58 Demenais (2018)60
5 Asthma NDFIP1/GNDPA1/SPRY4 Demenais (2018),60 Pickrell (2016)54
6 Asthma GPX5/TRIM27 Demenais (2018)60
6 Asthma, asthma + hay fever,
childhood onset asthma
HLAC/NOTCH4/MICB/HCP5/
MCCD1/HLADRB5/HLADRB1/
HLADQA1/HLA-DQB1/HLA-DPA1/
GRM4
Pickrell (2016),54 Hirota (2011),64
Demenais (2018),60 Ferreira
(2014),62 Noguchi (2011),66
Almoguera (2017)67
6 Asthma BACH2, GJA10, MAP3K7 Pickrell (2016),54 Demenais (2018)60
7 Asthma, childhood asthma +
exacerbations
CDHR3 Bonnelykke (2014),58 Pickrell
(2016)54
8 Childhood onset asthma SLC30A8 Noguchi (2011)66
8 Asthma, asthma + hay fever TPD52, ZBTB10 Demenais (2018),60 Pickrell
(2016),54 Ferreira (2014)62
9 Asthma, childhood asthma +
exacerbations, asthma + hay
fever
IL33/RANBP6 Ferreira (2014),62 Moffatt (2010),63
Torgerson (2011),56 Pickrell
(2016),54 Demenais (2018),60
Bonnelykke (2014)58
9 Asthma EQTN Almoguera (2017)67
10 Asthma GATA3/CELF2 Hirota (2011),64 Demenais (2018),60
Pickrell (2016)54
11 Asthma + hay fever LRRC32/C11orf30/EMSY Ferreira (2011),55 Ferreira (2014),62
Pickrell (2016),54 Demenais
(2018)60
12 Asthma IKZF4/STAT6/NAB2/LRP1 Hirota (2011),64 Demenais (2018),60
Pickrell (2016)54
14 Asthma RAD51B Pickrell (2016)54
15 Asthma RORA/NARG2/VPS13C Pickrell (2016),54 Demenais
(2018),60 Moffatt (2010)63
15 Asthma, asthma + hay fever SMAD3/SMAD6 Moffatt (2010),63 Pickrell (2016),54
Demenais (2018),60 Ferreira
(2014)62
16 Asthma, asthma + hay fever CLEC16A, DEXI, SOCS1 Ferreira (2014),62 Pickrell (2016),54
Demenais (2018)60
© 2018 The Authors
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118 538 non-asthmatic controls from multiple ethnic
groups which reported 18 loci (22 independent signals)
and novel loci at NDFIP1, GPX5 and ZNF652.60
TRANSLATIONAL APPROACHES:
GWAS TO FUNCTION
GWAS have identiﬁed many signals relating to respira-
tory disease, the challenge now is translating these
ﬁndings into biological insight. There are a number of
considerations to take into account when selecting an
association locus for follow-up analysis. Depending on
the variant in question, the types of analyses will vary
signiﬁcantly. In brief, a few considerations are whether
the SNP is coding or non-coding and whether there are
other SNP that are in linkage disequilibrium with the
sentinel SNP. Similarly, it must be considered if the
SNP (or SNPs) are expression quantitative trait loci
(eQTL), that is there is a relationship between the
genotype and mRNA levels, which would suggest regu-
latory function. This analysis been done on a large
scale with SNP identiﬁed as regulating mRNA levels in
lung tissue overlapping with SNP identiﬁed associated
with lung function demonstrating a clear enrichment of
cis and trans eQTL in the associated SNP.73 The various
translational approaches and considerations have been
extensively reviewed by Kheirallah et al.20 For the pur-
poses of this review, we will use AGER SNP rs2070600
as a case study of a coding region variant and variants
upstream of HHIP as a case study of a non-coding
variant.
Coding region variants
The AGER, encoding the RAGE protein, contains cod-
ing region variant rs2070600 which has been associated
with FEV1/FVC (Fig. 4).
37,38 The T allele of this variant
results in a substitution in the amino acid sequence of
RAGE from a glycine at position 82 to a serine.37,38 Fur-
ther analyses also showed the variant to be associated
with COPD, emphysema and gas trapping and lung
cancer, highlighting the need for further analysis of the
role of the gene and variant Ser82 in COPD.49,50,74,75
Miller et al. conducted a study showing that the
Ser82 variant had effects on lung function as well as
acting as an eQTL for soluble RAGE in both the serum
of UK smokers and RAGE production in a recombinant
cell system.76 RAGE is a member of the Ig superfamily
which when activated, by a diverse range of ligands,
has many downstream effects including inﬂammatory
regulation and cell migration, proliferation and adhe-
sion. RAGE expression was identiﬁed by immunohisto-
chemistry in the alveoli and bronchi of control and
COPD lungs. AGER mRNA is also expressed in the foe-
tal lung, with increasing levels across the pseudogland-
ular and canalicular stages of human lung
development. This ﬁnding correlated with protein
expression during lung development.76 The study also
showed that there was an association between
rs2070600T and higher FEV1 and FEV1/FVC as well as
providing evidence that individuals with the Ser82 vari-
ant had signiﬁcantly lower levels of serum sRAGE com-
pared to Gly82 genotype individuals.76
A reductionist RAGE recombinant cell model was
used to study the function effects of the different alleles
on the same genetic background and it was shown that
the Ser82 variant of the receptor resulted in lower
levels of secretion of soluble RAGE, demonstrating that
the speciﬁc variant has functional consequences.76
Rather counterintuitively, serum or plasma levels of
Table 1 Continued
Chromosome Phenotype (s) Gene(s) reported Reference
17 Asthma, childhood asthma +
exacerbations, asthma + hay
fever, childhood asthma,
moderate–severe asthma
ERBB2/PGAP3/MIEN1/ZPBP2/
GSDMB/ORMDL3/GSDMA
Demenais (2018),60 Pickrell
(2016),54 Moffatt (2010),63
Bonnelykke (2014),58 Torgerson
(2011),56 Moffatt (2007),31 Wan
(2012),68 Ferreira (2014)62
17 Asthma ZNF652, PHB Demenais (2018)60
22 Asthma IL2RB Moffatt (2010)63
BHR, Bronchial hyperresponsiveness; GWAS, genome-wide association studies.
Combined
P = 3.07 × 10–15
AGERCYP21A2
EGFL8
HLA-DRANOTCH4C4B
HLA-DRB1PBX2STK19
HLA-DRB5GPSM3STK19
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Figure 4 Region plot showing SNP associated with FEV1/FVC in
the AGER locus from the original SpiroMeta study. The x-axis
represents the chromosomal location and is annotated with
gene names and the y-axis shows the P-value, with more signiﬁ-
cant SNP higher up the axis. The key SNP (rs2070600) in this
region is highlighted ( ). AGER, Advanced Glycation End Prod-
uct Receptor; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; SNP, single nucleotide polymorphism. , r2 > 0.8;
, r2 > 0.5; , r2 > 0.2; , r2 < 0.2; , r2 unknown (Reproduced
from Repapi et al.,38 with permission).
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sRAGE in COPD patients are lower compared to con-
trols. This led to the hypothesis that lower levels of
sRAGE, which itself acts as a decoy to limit inﬂamma-
tion, actually may lead to greater RAGE-driven inﬂam-
mation in COPD.76 While the relationship between
genetics, lung function, sRAGE levels and COPD is not
fully deﬁned, these ﬁndings provide evidence that the
Ser82 variant, discovered through GWAS, is important
for RAGE function in COPD and began to explain the
underlying biological processes behind this association.
Non-coding region variants
The majority of SNP identiﬁed through GWAS localize
outside of protein coding regions, indicating that regu-
lation of gene expression is likely to be important in
disease processes.77 As an example, a number of SNP
near the HHIP gene on chromosome 4q31 have been
strongly associated with pulmonary function and
COPD.33,37,38 HHIP codes for a protein which is likely to
be an important regulator in a number of pathways
including those important for lung development.
HHIP mRNA and protein expression are reduced in
COPD lung tissues. Two SNP, from the haplotype asso-
ciated with COPD risk, rs6537296 and rs1542725, lie
within an HHIP enhancer region.78 These SNP have
been shown to modulate expression of HHIP, suggest-
ing that reduced expression of HHIP may be involved
in the pathogenesis of COPD.78 To determine the bio-
logical mechanism underlying the inﬂuence of HHIP
on COPD susceptibility, a knockdown cell model was
used.79 Silencing of the gene resulted in differential
expression of nearly 300 genes in the bronchial epithe-
lial cell line Beas-2B.79 Interestingly, there was enrich-
ment for variants associated with COPD and seven of
these genes were found to be differentially expressed in
human COPD and control lung tissues.79 Additional
analyses found enrichment for extracellular matrix
genes and genes involved in cell growth.79 The func-
tionality of the speciﬁc SNP in the long range enhancer
was also demonstrated using promoter–reporter
approaches.79 The authors showed that HHIP regulates
extracellular matrix remodelling and cell growth path-
ways and hypothesized that by doing so, HHIP might
inﬂuence smoke-induced COPD susceptibility.79 The
HHIP case demonstrates how SNP in a non-coding
region can begin to reveal mechanisms underlying dis-
ease process and highlight key pathways and genes for
further study.
CONCLUSION AND FUTURE
DIRECTIONS
To date, a large number of loci have been associated
with lung function, COPD and asthma using GWAS
particularly through recent consortia approaches maxi-
mizing sample sizes and improved imputation. While
the last decade or so has been promising in terms of
number of genes and variants associated with respira-
tory disease, there is still considerable work to do to
translate these ﬁndings into clinical practice. In the
future, translation of GWAS signals will be further facil-
itated by improved annotation of the human genome
and improved eQTL data sets as well as advances in
molecular and cell biology techniques such as clusters
of regularly interspaced short palindromic repeats
(CRISPR)/Cas9 gene editing to ultimately identify
causal variants and mechanisms leading to new under-
standing and opportunities for therapies.
GWAS in asthma support genes involved in innate
and adaptive immune responses being particularly
important in the disease process (e.g. MICB, CD247,
IL13, IL33, LRCC32, HLA, CLEC16A and GATA3), epi-
thelial barrier/function (e.g. IL33 and TSLP) or airway
structural changes (e.g. ORMDL3 and GSDMB). In the
lung function/COPD signals, there is an overrepresen-
tation of genes involved in developmental pathways
(e.g. CDON, PTCH1, PTHLH, TGFB2 and HHIP), elastic
ﬁbres (e.g. EFEMP1, TGFB2, LTBP4, MFAP2 and
FBLN5) and signals overlapping epigenetic marks.
Variants identiﬁed through GWAS only account for a
small percentage of the heritability with the known
lung function signals accounting for 9.6%, 6.4% and
14.3% of the heritability for FEV1, FVC and FEV1/FVC,
respectively.43 In asthma, 2.5% of heritability is esti-
mated to be due to SNP discovered through GWAS.70
This missing heritability is often attributed to the limi-
tations of GWAS and it is a fact that GWAS only detect
common variants and ignore other types of genomic
variation such as rare variants and copy number varia-
tions. GWAS also cannot inform on gene–environment
interactions, epigenetics or epistasis.80 Of course, it
may also just be likely that many variants which do not
reach genome-wide signiﬁcance may actually be true
associations contributing to the overall heritability.
The availability of affordable whole-genome and/or
whole-exome sequencing (WGS/WES) approaches
promises to enhance our ability to identify genetic asso-
ciations.26,30 One limitation of the arrays is that they do
not cover all genetic variants in the genome and
although imputation and array designs have addressed
this limitation to an extent, WGS gives the potential to
identify all the variants in the genome and therefore
improve our ability to ﬁne-map regions of interest.30
A recent paper used WGS to sequence 821 individuals
with severe COPD and 973 controls.81 They performed
single-variant and grouped-variant analyses and,
importantly, assessed the overlap of variants found for
COPD between array-based GWAS and sequencing.
The only statistically signiﬁcant variants were in the
well-known and previously mentioned HHIP locus;
however, other variants approaching signiﬁcance were
located in a previously reported loci, CHRNA5, TNS1
and SERPINA6/SERPINA1. 81 Importantly, WGS identi-
ﬁed >20 million novel variants which included >10 000
variants in regions previously identiﬁed in GWAS for
COPD.81 While the study provided evidence that novel
and rare variants can be detected by sequencing, it also
highlighted the need for considerably larger sample
sizes to ﬁnd variants of signiﬁcance like those used in
meta-analyses of GWAS.
With advances in technology and decrease in the
price of sequencing in the coming years, it is antici-
pated that SNP array GWAS will be replaced by WGS
eventually. However, GWAS by SNP array with large
sample sizes have proven and continues to be a power-
ful tool for gene discovery. Using combinations of high-
© 2018 The Authors
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throughput methods including GWAS, sequencing,
transcriptomics and proteomics is starting to provide
signiﬁcant advances in our understanding. These tech-
nological advances as well as greater consideration of
environmental factors and improved phenotype data
are keys to providing insight into these diseases at the
molecular level.
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